Impact of Pharmacologic Interventions on Peripheral Artery Disease

Pineda, Javier; Kim, Esther S.H.; Osinbowale, Olusegun

doi:10.1016/j.pcad.2014.12.001

Cited by 6 publications

(2 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Development of a therapy capable of preventing tissue necrosis and of favouring revascularization is crucial for patients with critical ischemia [108]. Although marine polysaccharides have numerous interesting effects on coagulation, thrombosis, inflammation and angiogenesis, their clinical development is hindered by their heterogeneity.…”

Section: -Conclusionmentioning

confidence: 99%

Use of Marine Compounds to Treat Ischemic Diseases

Boisson-Vidal

2018

Blue Biotechnology

View full text Add to dashboard Cite

Section: -Conclusionmentioning

confidence: 99%

Use of Marine Compounds to Treat Ischemic Diseases

Boisson-Vidal

2018

Blue Biotechnology

View full text Add to dashboard Cite

“…1,2 Platelets have been considered to play a central role in the development of arterial thrombosis in patients with systemic atherosclerotic vascular disease, including PAD. 3 The benefits of antiplatelet therapy for the secondary prevention of cardiovascular events in patients with PAD have been evaluated, and antiplatelet therapy, notably P2Y 12 inhibition, has resulted in reduced risk of major adverse cardiovascular events in these patients. 1,4 On the basis of this evidence, treatments with antiplatelet therapy for the prevention of cardiovascular events in PAD patients have been recom-mended.…”

mentioning

confidence: 99%

Prasugrel, a Platelet P2Y ₁₂ Receptor Antagonist, Improves Abnormal Gait in a Novel Murine Model of Thrombotic Hindlimb Ischemia

Ohno

Tomizawa

Mizuno

et al. 2016

JAHA

View full text Add to dashboard Cite

BackgroundThe efficacy of P2Y12 inhibition for the prevention of cardiovascular events in patients with peripheral arterial disease (PAD) has been established. However, the therapeutic effects on ischemic limb complications are less clear. Accordingly, we aimed to develop a novel murine model of thrombotic hindlimb ischemia to reflect that found in patients with PAD exhibiting ischemic limb symptoms. We further investigated the effects of P2Y12 deficiency and P2Y12 inhibition by prasugrel in this model.Methods and ResultsThrombus formation induced by application of ferric chloride to the femoral artery resulted in a significant reduction in blood flow in the injured limb. In gait analysis using the CatWalk system, moderate difficulties in grounding and weight bearing of the ischemic limb, including reduction of maximum contact area and stance phase duration and increasing in swing phase duration in the ischemic limb, were observed in this model. Blood flow reduction and gait abnormalities gradually recovered over 21 days to levels present before arterial injury. Compared to wild‐type (WT) mice, significant increases in blood flow and improvement in gait were observed in P2Y12‐deficient mice. In addition, daily oral administration of prasugrel (3 mg/kg per day) to WT mice resulted in significant inhibition of blood flow reduction and gait abnormalities to levels found in P2Y12 deficient mice.ConclusionsAcute femoral artery thrombosis resulted in hindlimb ischemia and moderate gait abnormalities in mice. In addition, the present study suggests a possible role of P2Y12 in the complications with thrombotic limb ischemia.

show abstract